Keywords: new, data, b-ms, serzone, bristol-myers, squibb, presented
New Data With B-MS' Serzone
Article | 03 July 1997
Bristol-Myers Squibb presented data at the WCBP which demonstrated thatSerzone (nefazodone) is effective in the treatment of severely-depressed hospitalized patients.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
